Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...

The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...